Redesign Science
Redesign Science is a pre-revenue, New York-based computational biotechnology company that combines physics-based molecular dynamics with generative AI through its NUVO™ platform to discover first-in-class small molecule Targeted Protein Interaction Modulators (TPIM™) for oncology, autoimmune, and rare disease indications.
- Company typePrivate
- Founded2017
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Redesign Science firmographics
Firmographics- Name
- Redesign Science
- Legal name
- Redesign Science
- Website
- https://redesignscience.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Redesign Science is a pre-revenue, New York-based computational biotechnology company that combines physics-based molecular dynamics with generative AI through its NUVO™ platform to discover first-in-class small molecule Targeted Protein Interaction Modulators (TPIM™) for oncology, autoimmune, and rare disease indications.
- Ownership category
- akta.pro rank
Redesign Science industry classification
Industry- Product category
- Computational Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
Keywords
Where Redesign Science is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Redesign Science business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Therapeutic Pipeline Development: Pre-revenue biotech company developing small molecule therapeutics. Revenue will be generated through partnering deals with pharmaceutical companies, licensing agreements, or eventual product sales upon regulatory approval.
Distribution channels1 record
Marketing channels2 records
Redesign Science product offering
Product offeringCore offering
Redesign Science develops the NUVO™ platform, which combines physics-based atomic-level molecular dynamics with generative AI to identify druggable binding sites on proteins and design novel small molecules. The platform powers the company's internal pipeline of first-in-class Targeted Protein Interaction Modulators (TPIM™) across oncology, autoimmune, and rare disease indications, intended to be monetized through pharmaceutical licensing and partnership deals.
Product overview
Redesign Science operates as a unified platform-plus-products architecture centered on its NUVO™ technology platform, which integrates physics simulation with generative AI. The NUVO platform consists of three core sub-products: NUVO Matisse (enhanced sampling physics for structural data), NUVO Picasso (generative AI for novel compounds), and NUVO Cézanne (machine learning for predictive scoring). This platform serves the company's internal therapeutics pipeline of first-in-class small molecule TPIM™ (Targeted Protein Interaction Modulators) across oncology, autoimmune, and rare disease indications.
Differentiator
Problem solved
Functional benefit
Products and services
- NUVO™ Platform Integrated physics, chemistry, and synthetic data platform that combines physics simulation with generative AI to enable dynamic structure-based drug discovery and serves the company's internal small molecule therapeutics pipeline.
- TPIM™ (Targeted Protein Interaction Modulators) First-in-class small molecule therapeutic modality developed by Redesign Science to modulate targeted protein-protein interactions and provide unprecedented control over cellular biology, pursued across oncology, autoimmune, and rare disease indications.
Companies that use Redesign Science
Customer profileSegments1 record
Ideal customer profiles1 record
Redesign Science technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Redesign Science partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights5 records
Redesign Science competitors and assessment
Company assessmentDirect peers
- Insitro: Machine learning-driven drug discovery company combining high-throughput biology with predictive models for small molecule therapeutics. Comparable platform-plus-pipeline business model with pharma collaborations.
- Atomwise: AI-focused small molecule drug discovery company using structure-based deep learning to screen billions of compounds. Comparable as a tech-first platform pursuing pharma partnerships and internal programs.
- Schrödinger, Inc. Public computational drug discovery company combining physics-based molecular simulation with ML for small molecule discovery. Most directly comparable to Redesign Science given the shared physics-first platform philosophy and pharma-licensing business model.
- Relay Therapeutics: Clinical-stage precision medicine company using protein motion visualization and computational chemistry to discover small molecule drugs. Closely aligned with Redesign Science's NUVO Matisse approach to leveraging dynamic protein structures for drug discovery.
- XtalPi: AI and physics-based drug discovery company combining quantum physics, molecular dynamics, and AI for small molecule and crystal design. Directly comparable technology stack and CRO/partnership model.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning for small molecule therapeutics. Comparable as a publicly-listed AI/biotech platform advancing an internal pipeline plus pharma partnerships.
Broad incumbents
- Isomorphic Labs: Alphabet-backed AI drug discovery company leveraging DeepMind's protein structure prediction (AlphaFold) for drug discovery. Broad incumbent with significantly more capital and the ability to leverage Alphabet's AI infrastructure.
Emerging players
- Iambic: AI-driven drug discovery company combining physics-based modeling with generative AI for small molecule design. Emerging player with significant overlap to Redesign Science's integrated physics+AI platform approach.
- Generate Biomedicines: Generative biology company using machine learning to design novel protein therapeutics. Partially overlapping as a tech-first platform company using AI for therapeutic design, though focused on biologics rather than small molecules.
- Celeris Therapeutics: AI-driven degrader and small molecule discovery company using graph neural networks and physics-based approaches. Comparable as an emerging computational platform pursuing difficult-to-drug targets through AI/ML approaches.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Redesign Science social profiles
Digital presenceRedesign Science financial estimates
Financial estimateRevenue estimate
Valuation estimate
Redesign Science leadership team
Management profileNumber of profiles
Profiles1 record
Redesign Science funding detail
Funding detailFunding overview
Funding rounds2 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Redesign Science M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Redesign Science
What does Redesign Science do?
Redesign Science develops the NUVO™ platform, which combines physics-based atomic-level molecular dynamics with generative AI to identify druggable binding sites on proteins and design novel small molecules. The platform powers the company's internal pipeline of first-in-class Targeted Protein Interaction Modulators (TPIM™) across oncology, autoimmune, and rare disease indications, intended to be monetized through pharmaceutical licensing and partnership deals.
Is Redesign Science a public or private company?
Redesign Science is a private company. It is classified as venture growth investor backed and is currently operating.
When was Redesign Science founded?
Redesign Science was founded in 2017. It employs 11 to 50 people.
Where is Redesign Science based?
Redesign Science is headquartered in New York, United States, in the North America region.
How does Redesign Science make money?
One revenue line is on record: therapeutic Pipeline Development.
Who are Redesign Science's main competitors?
Direct peers on record are Insitro, Atomwise, Schrödinger, Inc., Relay Therapeutics, XtalPi and Recursion Pharmaceuticals. Isomorphic Labs is listed as a broad incumbent. Emerging players are Iambic, Generate Biomedicines and Celeris Therapeutics.
Does Redesign Science have an API?
No public API is recorded for Redesign Science.
What industry is Redesign Science in?
Redesign Science's product category is Computational Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening). Its NAICS code is 541714 and its SIC code is 8731.